ASCO 2018 News : Episode 5

Practice Changes for Use of Immunotherapy in NSCLC

Video

Related Videos
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Nan Chen, MD
Julia Foldi, MD, PhD
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Margaret E. Gatti-Mays, MD, MPH, FACP, of The Ohio State University Comprehensive Cancer Center
Eric Vallieres, MD, FRCSC
Related Content
FDA

FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies

April 19th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
David L. Porter, MD

Call for Boxed Warning for Secondary Malignancies on CAR T-Cell Therapies Raises Alarm, But Key Questions Remain

April 18th 2024
Article
Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

January 11th 2024
Podcast
Paul G. Richardson, MD, of Dana-Farber Cancer Institute

Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma

April 18th 2024
Article
Breast Cancer | adobe.stock.com

Durvalumab Plus Trastuzumab/Pertuzumab Elicits Responses in HER2-Enriched Breast Cancer

April 16th 2024
Article